ROHTESH S MEHTA to Protein Kinase Inhibitors
This is a "connection" page, showing publications ROHTESH S MEHTA has written about Protein Kinase Inhibitors.
Connection Strength
0.136
-
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 12 02; 138(22):2278-2289.
Score: 0.065
-
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019 12; 60(13):3292-3295.
Score: 0.055
-
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
Score: 0.016